Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines.
10.4048/jbc.2015.18.4.329
- Author:
Sonia AVILA-ARROYO
1
;
Gema Santamaria NUNEZ
;
Luis Francisco GARCIA-FERNANDEZ
;
Carlos M GALMARINI
Author Information
1. Cell Biology and Pharmacogenomics Department, PharmaMar S.A., Madrid, Spain. cgalmarini@pharmamar.com
- Publication Type:In Vitro ; Original Article
- Keywords:
BRCA1 protein;
Breast neoplasms;
Drug combinations;
Olaparib;
Trabectedin
- MeSH:
Blotting, Western;
BRCA1 Protein;
Breast Neoplasms*;
Breast*;
Cell Cycle;
Cell Death;
Cell Line*;
Comet Assay;
DNA Breaks, Double-Stranded;
DNA Damage;
DNA, Recombinant;
Drug Combinations;
Flow Cytometry
- From:Journal of Breast Cancer
2015;18(4):329-338
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Trabectedin induces synthetic lethality in tumor cells carrying defects in homologous recombinant DNA repair. We evaluated the effect of concomitant inhibition of nucleotide-excision repair and poly (ADP-ribose) polymerase (PARP) activity with trabectedin and PARP inhibitors, respectively, and whether the synthetic lethality effect had the potential for a synergistic effect in breast cancer cell lines. Additionally, we investigated if this approach remained effective in BRCA1-positive breast tumor cells. METHODS: We have evaluated the in vitro synergistic effect of combinations of trabectedin and three different PARP inhibitors (veliparib, olaparib, and iniparib) in four breast cancer cell lines, each presenting a different BRCA1 genetic background. Antiproliferative activity, DNA damage, cell cycle perturbations and poly(ADP-ribosyl)ation were assessed by MTT assay, comet assay, flow cytometry and western blot, respectively. RESULTS: The combination of trabectedin and olaparib was synergistic in all the breast cancer cell lines tested. Our data indicated that the synergy persisted regardless of the BRCA1 status of the tumor cells. Combination treatment was associated with a strong accumulation of double-stranded DNA breaks, G2/M arrest, and apoptotic cell death. Synergistic effects were not observed when trabectedin was combined with veliparib or iniparib. CONCLUSION: Collectively, our results indicate that the combination of trabectedin and olaparib induces an artificial synthetic lethality effect that can be used to kill breast cancer cells, independent of BRCA1 status.
